Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- APRE
- Price
- 1.64
- Stock movement down
- -0.13 (-7.51%)
- Company name
- Aprea Therapeutics Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 9.52M
- Ent value
- -11.78M
- Price/Sales
- 9.96
- Price/Book
- 0.43
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -34.57%
- 1 year return
- -61.07%
- 3 year return
- -52.81%
- 5 year return
- -69.71%
- 10 year return
- -
Last updated: 2025-08-27
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
APRE does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 9.96 |
| Price to Book | 0.43 |
| EV to Sales | -12.32 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 5.83M |
| EPS (TTM) | -2.27 |
| FCF per share (TTM) | -2.33 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 956.22K |
| Gross profit (TTM) | 939.77K |
| Operating income (TTM) | -14.77M |
| Net income (TTM) | -13.51M |
| EPS (TTM) | -2.27 |
| EPS (1y forward) | -0.51 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 98.28% |
| Operating margin (TTM) | -1544.47% |
| Profit margin (TTM) | -1412.56% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 26.25M |
| Net receivables | 0.00 |
| Total current assets | 26.48M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 0.00 |
| Total assets | 26.89M |
| Accounts payable | 1.15M |
| Short/Current long term debt | 0.00 |
| Total current liabilities | 3.64M |
| Total liabilities | 4.95M |
| Shareholder's equity | 21.95M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -13.81M |
| Capital expenditures (TTM) | 24.04K |
| Free cash flow (TTM) | -13.83M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -61.54% |
| Return on Assets | -50.22% |
| Return on Invested Capital | -61.54% |
| Cash Return on Invested Capital | -63.02% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 1.75 |
| Daily high | 1.77 |
| Daily low | 1.62 |
| Daily Volume | 30K |
| All-time high | 990.60 |
| 1y analyst estimate | 10.50 |
| Beta | 1.58 |
| EPS (TTM) | -2.27 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | - |
Downside potential
Loading...
Downside potential data
| APRE | S&P500 | |
| Current price drop from All-time high | -99.83% | -3.04% |
| Highest price drop | -99.95% | -56.47% |
| Date of highest drop | 13 Feb 2023 | 9 Mar 2009 |
| Avg drop from high | -82.91% | -11.04% |
| Avg time to new high | 96 days | 12 days |
| Max time to new high | 1377 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
9.52M
Marketcap category
Small-cap
Description
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidates are APR-1051, an orally bioavailable small-molecule inhibitor of WEE1 kinase that is in Phase 1 clinical trial for the treatment of patients with advanced solid tumors with biomarkers; and ATRN-119, an ATR inhibitor, which is in Phase 1/2a clinical trial for solid tumor indications. The company is headquartered in Doylestown, Pennsylvania.
Employees
8
Website
Investor relations
-
SEC filings
CEO
Christian S. Schade
Country
USA
City
Boston
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page